SCHEMBL17125396

SCHEMBL17125396

Cc1cc(-c2ccc(-c3ccn(-c4ccc(C(=O)O)cc4)n3)o2)ccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RARA P10276 9/20 0.44
▸ RARB P10826 9/20 0.44
▸ RARG P13631 9/20 0.44
▸ SIRT5 Q9NXA8 1/20 0.42
▸ MEN1 O00255 4/20 0.42
▸ KMT2A Q03164 4/20 0.42
▸ POLB P06746 3/20 0.42
▸ KDM4E B2RXH2 2/20 0.42
▸ APEX1 P27695 2/20 0.42
▸ RPA1 P27694 2/20 0.42
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ RECQL P46063 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ NTSR1 P30989 1/20 0.40
▸ GALK1 P51570 1/20 0.40
▸ HPGD P15428 1/20 0.38
▸ XPA P23025 1/20 0.37
▸ ADH5 P11766 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17125414 0.92 KDM4E (0.52) RARARARBRARGSIRT5MEN1
SCHEMBL12872234 0.90 RPA1 (0.49) RARARARBRARGMEN1KMT2A
SCHEMBL12872236 0.79 KDM4E (0.48) MEN1KMT2APOLBKDM4EAPEX1
SCHEMBL29070695 0.73 ADH5 (0.47) RARGMEN1KMT2APOLBKDM4E
SCHEMBL27695766 0.72 HTT (0.52) MEN1KMT2APOLBKDM4EAPEX1
SCHEMBL182283 0.70 KCNJ1 (0.45) RARGMEN1KMT2APOLBKDM4E
SCHEMBL7141426 0.69 CYP19A1 (0.40) MAPT
SCHEMBL2708392 0.69 NPC1 (0.47) MEN1KMT2AKDM4EMAPTADH5
SCHEMBL2710612 0.68 KDM4E (0.58) MEN1KMT2APOLBKDM4EMAPT
SCHEMBL2712136 0.68 ALDH1A1 (0.47) MEN1KMT2APOLBKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150274674-A1 PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES PTC THERAPEUTICS, INC. (US) 2015-10-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150274674-A1 PYRAZOLE OR TRIAZOLE COMPOUNDS AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING SOMATIC MUTATION-RELATED DISEASES UPF1, RNMT, VHL RARA 3067/4885RARB 2833/4885RARG 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback